Jasper Therapeutics (NASDAQ:JSPR) Releases Quarterly Earnings Results, Misses Estimates By $0.12 EPS

Jasper Therapeutics (NASDAQ:JSPR) announced its quarterly earnings data on Monday. The company reported ($1.13) EPS for the quarter, missing the consensus estimate of ($1.01) by ($0.12), Zacks reports.

Jasper Therapeutics Stock Performance

Shares of NASDAQ JSPR traded down $0.00 during trading on Wednesday, hitting $1.70. 137,890 shares of the company were exchanged, compared to its average volume of 465,575. The company has a fifty day moving average price of $2.37 and a 200-day moving average price of $3.62. Jasper Therapeutics has a 12-month low of $1.60 and a 12-month high of $26.05. The firm has a market capitalization of $27.61 million, a PE ratio of -0.29 and a beta of 2.83.

Insider Activity at Jasper Therapeutics

In other news, Director Svetlana Lucas purchased 20,000 shares of the firm’s stock in a transaction that occurred on Monday, September 22nd. The stock was bought at an average price of $2.43 per share, for a total transaction of $48,600.00. Following the completion of the purchase, the director directly owned 20,000 shares of the company’s stock, valued at $48,600. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Judith Anne Shizuru purchased 41,000 shares of the company’s stock in a transaction that occurred on Monday, September 22nd. The stock was bought at an average price of $2.43 per share, for a total transaction of $99,630.00. Following the transaction, the director directly owned 156,901 shares in the company, valued at $381,269.43. This trade represents a 35.38% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 143,000 shares of company stock valued at $347,490 in the last quarter. Corporate insiders own 4.60% of the company’s stock.

Institutional Investors Weigh In On Jasper Therapeutics

A number of large investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC acquired a new position in shares of Jasper Therapeutics in the first quarter worth $46,000. Engineers Gate Manager LP purchased a new position in Jasper Therapeutics in the 2nd quarter worth approximately $78,000. XTX Topco Ltd purchased a new stake in shares of Jasper Therapeutics during the second quarter worth about $152,000. Marshall Wace LLP bought a new position in Jasper Therapeutics during the 2nd quarter valued at $281,000. Finally, JPMorgan Chase & Co. increased its holdings in shares of Jasper Therapeutics by 1,074.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 65,088 shares of the company’s stock valued at $361,000 after acquiring an additional 59,547 shares during the last quarter. 79.85% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

JSPR has been the topic of a number of research analyst reports. BTIG Research dropped their price objective on shares of Jasper Therapeutics from $20.00 to $7.00 and set a “buy” rating on the stock in a report on Monday, September 22nd. UBS Group reduced their price objective on Jasper Therapeutics from $29.00 to $25.00 and set a “buy” rating for the company in a research note on Friday, August 15th. Evercore ISI decreased their target price on Jasper Therapeutics from $20.00 to $14.00 and set an “outperform” rating for the company in a report on Monday, September 22nd. JMP Securities cut their price target on shares of Jasper Therapeutics from $12.00 to $6.00 and set a “market outperform” rating on the stock in a report on Monday, September 22nd. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Wednesday, October 8th. Six equities research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Jasper Therapeutics presently has a consensus rating of “Hold” and an average price target of $25.63.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.